Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P30291

UPID:
WEE1_HUMAN

ALTERNATIVE NAMES:
Wee1A kinase

ALTERNATIVE UPACC:
P30291; B3KVE1; D3DQV0

BACKGROUND:
The Wee1-like protein kinase, known for its alternative name Wee1A kinase, serves as a crucial negative regulator of mitosis entry by mediating the phosphorylation of CDK1 on 'Tyr-15'. This action inactivates the cyclin B1-CDK1 complex, primarily during the G2 phase, and prevents premature mitotic entry. The kinase's activity is intricately tied to the cell cycle, increasing in the S and G2 phases and decreasing at M phase through hyperphosphorylation.

THERAPEUTIC SIGNIFICANCE:
Exploring the intricacies of Wee1-like protein kinase's function offers a promising avenue for developing novel therapeutic approaches. Given its essential role in controlling cell cycle progression, targeting this kinase could provide a strategic pathway for treating proliferative disorders such as cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.